Cannabis-based medicinal products (Sativex)

Status:

Do Not Prescribe (DNP), Red, Green - after consultant/specialist initiation

Decision Date:

December 2019

Comments

Cannabis - based products listed in NICE NG144 include:

• Nabilone
• THC:CBD (combination of delta-9-tetrahydrocannabinol with cannabidiol - Sativex)
• Dronabinol
• THC (delta-9-tetrahydrocannabinol)
• Cannabidiol (Epidyolex) with clobazam

JAPC classification for each NICE indication:

GREEN after consultant/specialist initiation:

• NICE NG144: Spasticity in adults with multiple sclerosis (ICB commissioned).
• See primary care prescribing guideline for Sativex. (Decision date - September 2022).
• There is a requirement to maintain patient registry for Sativex. The consultant/specialist is responsible for registering the patient. NHSE patient registry. 

RED:

• NICE NG144: Seizures associated with Lennox-Gastaut syndrome & Dravet syndrome.  (See also TA614 & TA615 below).  (NHSE commissioned).
• NICE TA614 - Cannabidiol (Epidyolex) with clobazam for treating seizures associated with Dravet syndrome.  (NHSE commissioned).  (Decision date - January 2020).
• NICE TA615 - Cannabidiol (Epidyolox) with clobazam for treating seizures associated with Lennox-Gastaut syndrome.  (NHSE commissioned) (Decision date - January 2020).
• NICE TA873 - Cannabidiol for treating seizures caused by tuberous sclerosis complex. (NHSE commissioned) (Decision date - April 2023)

Do Not Prescribe (DNP):

• NICE NG144 - intractable nausea and vomiting.  (NHSE commissioned).
• NICE NG144 - chronic pain.  (NHSE commissioned).
• NICE NG144 - severe treatment - resistant epilepsy.  (NHSE commissioned).

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again